ACE and Hypertension: Analyses of several clinical trials using antihypertensive agents in patients with and without hypertension have demonstrated that RAS blockade significantly reduces the risk of new-onset diabetes in patients treated with ACE inhibitors (41–44) or ARBs (45–48), compared with diuretics, β-blockers, CCBs, or placebo (Table 3).